This is a working overview of melanogenesis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-30. Anything still debated is marked as such rather than presented as settled.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
It can be attributed to the first pass through the liver with oral administration and to the high oral bioavailability and strong resistance to hepatic metabolism of these agents. Enobosarm has no estrogenic activity, either intrinsic to itself or via its metabolites. As a result, the drug is not expected to have feminizing effects or risk of gynecomastia (breast development) nor to stimulate estrogen-sensitive breast cancer. SARMs like enobosarm are not ideal agents for androgen replacement therapy as they are not expected to reproduce the full spectrum of effects of testosterone and other androgens, including not only AR-mediated effects but also notably aromatization into estrogen and required physiological estrogenic effects in bone and brain. Enobosarm has been found to be a weak antagonist of the progesterone receptor and hence might have some capacity for antiprogestogenic effects. Aside from its weak interaction with the progesterone receptor, enobosarm is highly selective for the AR and does not bind to other nuclear hormone receptors.
Separation is achieved based on the polarity differences among functional groups such as amines, acids, metal complexes, etc. as well as their steric properties, while in reversed-phase chromatography, a partition mechanism typically occurs for the separation by non-polar differences. In the aqueous normal-phase chromatography the support is based on a silica with "hydride surface" which is distinguishable from the other silica support materials, used either in normal phase, reversed phase, or hydrophilic interaction chromatography. Most silica materials used for chromatography have a surface composed primarily of silanols (-Si-OH). In a "hydride surface" the terminal groups are primarily -Si-H. The hydride surface can also be functionalized with carboxylic acids and long-chain alkyl groups. Mobile phases for ANPC are based on organic solvents as bulk solvents (such as methanol or acetonitrile) with a small amount of water as a modifier of polarity; thus, the mobile phase is both "aqueous" (water is present) and "normal phase type" (less polar than the stationary phase). Thus, polar solutes (such as acids and amines) are more strongly retained, with the ability to affect the retention, which decreases as the amount of water in the mobile phase increases. Typically the mobile phases are rich with organic solvents, with amount of the nonpolar solvent in the mobile phase at least 60% or greater to reach minimal required retention.
== Applications == Lysine carboxypeptidase is found within the plasma and is used to inactivate certain proteins; this functions to protect the body from potent molecules that may escape from tissues. The most well-studied protein that is inactivated by this enzyme is bradykinin (along with other kinins such as kallidin) which contributes to inflammation and blood pressure regulation. However, the primary way bradykinin is degraded is by angiotensin I converting enzyme (ACE). Lysine carboxypeptidase is still important nonetheless, especially if a patient is receiving ACE inhibitors to treat a condition. Kinins are most often autocrine or paracrine hormones and are thus often restricted in location. If too much of the hormone escapes into the blood and levels rise too high, this can have harmful effects on the body. Lysine carboxypeptidase prevents this from happening. This enzyme has also proven to be important in inactivating anaphylatoxins which are inflammation-inducing proteins used in immune responses. Similarly to kinins, harmful effects can occur if too much of these proteins accumulate in the blood. Other molecules that this enzyme is involved in modifying, and consequently regulating, include creatine kinase, hemoglobin, stromal cell-derived factor-1α (SDF-1α), plasminogen receptors, and enkephalins. The enzymatic interaction with creatine kinase releases one lysine from each of two subunits and modifies its function. With hemoglobin, it speeds up the dissociation of the tetramer into dimers and increases its oxygen affinity.
Sources: en.wikipedia.org
Enantiomers may not be isolable if there is an accessible pathway for racemization (interconversion between enantiomorphs to yield a racemic mixture) at a given temperature and timescale. For example, amines with three distinct substituents are chiral, but with few exceptions (e.g. substituted N-chloroaziridines), they rapidly undergo "umbrella inversion" at room temperature, leading to racemization. If the racemization is fast enough, the molecule can often be treated as an achiral, averaged structure.
== Death and legacy == Boyd Orr died on 25 June 1971 in Brechin, Scotland; he was 90 years old. His grave is at Stracathro Kirkyard, Angus. The University of Glasgow's Boyd Orr Building and the Boyd Orr Centre for Population and Ecosystem Health are named after him, and the university's Hunterian Museum holds his Nobel Peace Prize medal. There is a street named for Boyd Orr in his home town of Kilmaurs in Ayrshire, as well as others in Aberdeen, Brechin, Laurencekirk, Penicuik, Saltcoats and Strathaven. There is also a road named after him in Harare, Zimbabwe.
The new 2nd district encompasses most of the northern and northeastern suburbs of Houston, including The Woodlands, Spring, Kingwood, New Caney, Humble, and Atascocita, as well as the Willowbrook area of Houston itself. The incumbent is Republican Dan Crenshaw, who was re-elected with 65.7% of the vote in 2024, will not be on the general election ballot since he was defeated in the primary by State Representative Steve Toth. Donald Trump and Ted Cruz won 60.8% and 58.0% of the vote, respectively, in this district in 2024.
Sources: en.wikipedia.org
== In radioactive decay == Secular equilibrium can occur in a radioactive decay chain only if the half-life of the daughter radionuclide B is much shorter than the half-life of the parent radionuclide A. In such a case, the decay rate of A and hence the production rate of B is approximately constant, because the half-life of A is very long compared to the time scales considered. The quantity of radionuclide B builds up until the number of B atoms decaying per unit time becomes equal to the number being produced per unit time. The quantity of radionuclide B then reaches a constant, equilibrium value. Assuming the initial concentration of radionuclide B is zero, full equilibrium usually takes several half-lives of radionuclide B to establish. The quantity of radionuclide B when secular equilibrium is reached is determined by the quantity of its parent A and the half-lives of the two radionuclide. That can be seen from the time rate of change of the number of atoms of radionuclide B:
=== EU resources === "The "hormone" case: Background and history". The 2000 Queluz EU-US Summit, 2000-05-31. European Commission Commissioner for External Relations. 24 May 2000. Archived from the original on 6 March 2008.
=== Defunct === Liaison Committee for a Revolutionary Workers International, founded by former militants of the Argentinian MAS and PO Committee for a Workers' International (CWI), 1974–2019 – split into Committee for a Workers' International (Refounded) and International Socialist Alternative Coordinating Committee for the Refoundation of the Fourth International, CCRCI (2004-2020) International League for the Reconstruction of the Fourth International (ILRFI), 1976–1995 Workers International to Rebuild the Fourth International (WIRFI) International Revolutionary Marxist Tendency (TMRI), 1965–1992 Permanent Revolution Revolutionary Workers Ferment (Fomento Obrero Revolucionario, FOR) Trotskyist International Liaison Committee, 1979–1984 Tendencia Cuartainternacionalista Fourth International (ICR), also called FI (La Verité) or FI (International Secretariat) 1981–2015 Socialist Network (Post-Trotskyist, split from IMT) International Trotskyist Opposition] (ITO) 2022–2025 (Dissolved into LIS-ISL) League for the Fifth International (L5I), founded by expelled members of the IST. (1989-2025)
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.